ClinicalTrials.gg
CompletedNCT01607905Updated Jan 26, 2023Results posted

Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer

A Phase 1 interventional study of Selinexor and Acetaminophen in Solid Tumor, sponsored by Karyopharm Therapeutics Inc. Completed at 6 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-26.

Sponsored by Karyopharm Therapeutics Inc · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
192
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 330 studies in Carcinoma, Squamous Cell with a site in United States — 68 open to participants now, 99 under way, 6 of them phase 3. Carcinoma, Squamous Cell · United States.

Enrollment
45th of 280
192 · median 37
Started
2012
with 10 others
Phase 1
80 of 330
19 open now
Registered
111th of 330
by date

Among the 330 studies in Carcinoma, Squamous Cell with a site in United States, this one is the 45th largest by enrollment of the 280 interventional ones that give a count, is one of 11 that started in 2012, is one of 80 in phase 1, and was the 111th registered.

Carcinoma, Squamous Cell

629 studies on the registry are indexed under Carcinoma, Squamous Cell; 135 are open to participants now.

Browse Carcinoma, Squamous Cell studies →

Open to participants now

68 of the 330 studies in Carcinoma, Squamous Cell with a site in United States are open now. Recruiting first, the newest first:

63 more — sign in →

All 68 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 102 Carcinoma, Squamous Cell studies recruiting now, 86 (84%) set no upper age limit and 8 (8%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 330 studies in Carcinoma, Squamous Cell with a site in United States, or all of them as a file.
02

Study summary

Phase 1 study to evaluate the safety and tolerability of selinexor and determine the Recommended Phase 2 Dose (RP2D) of selinexor for advanced or metastatic solid tumor malignancies.

Read the detailed description

This is a phase 1a and phase 1b, open-label, dose-escalation study to evaluate the safety and tolerability of selinexor and determine the RP2D in patients with solid tumor malignancies.

03

Conditions studied

  • Solid Tumor

Keywords

  • Selinexor
  • KPT-330
  • Squamous Cell Carcinoma
  • Glioblastoma multiforme
  • Adenocarcinoma
  • Melanoma
  • Colorectal cancer
  • Gynecological cancer
  • Castrate-resistant Prostate Cancer
  • Other solid tumors
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Dose Escalation Phase: Patients with advanced or solid tumors for which no standard therapy is available. For Schedule 6 only: patients with colorectal cancer with liver metastasis.

    Dose Expansion Phase: Previously treated, metastatic or advanced recurrent with 1 of the following diagnoses, which has been confirmed histologically or cytologically:

    • Up to 12 patients with metastatic colorectal cancer with a history of progression or recurrence following prior fluoropyrimidine, irinotecan and platinum containing regimens as well as bevacizumab. In addition, patients with Kras wild type tumor must have received at least one EGFR blocker.
    • Up to 6 patients with histological or cytological documentation of advanced ovarian, fallopian tube, or primary peritoneal carcinoma with a history of progression or recurrence following at least one prior platinum and one taxane based chemotherapy
    • Up to 12 patients with incurable Squamous cell cancers as follows:

      1. A minimum of 4 Squamous Non-Small Cell Lung Cancer (Sq-NSCLC)
      2. A minimum of 4 Squamous Cell Carcinomas of the Head and Neck (Sq-HNC)
      3. Squamous Cell Carcinoma of the Cervix (SqCC) All patient with Squamous Cell Carcinomas should have a documented history of progression or recurrence following at least one prior platinum based chemotherapy or chemotherapy/radiation containing regimen
    • Up to 6 patients with castration-resistant prostate cancer (CRPC) that was confirmed as adenocarcinoma of the prostate and with evidence of metastatic disease on bone scan or other imaging. Patient must have progressive disease after at least one hormonal treatment and one cytotoxic therapy e.g. with docetaxel, mitoxantrone.
    • Up to 12 patients with unresectable metastatic melanoma whose disease progressed on at least 1 prior systemic anticancer regimen (chemotherapy, biological or immunotherapy, or targeted therapy). Enrollment to this cohort may have been stopped before reaching 12 patients once the dose-escalation portion of the study was completed.
    • Approximately 6 patients with advanced or metastatic solid tumors were to be enrolled on Schedule 8 at a starting dose of 35 mg/m\^2 to assess general tolerability and activity of selinexor.
  2. Dose Escalation Phase: Patients have exhausted, or be deemed to not benefit from, further conventional therapy and have evidence of progressive disease on study entry.

Both Dose Escalation and Expansion Phases: There is no upper limit on the number of prior treatments provided that all inclusion criteria are met and exclusion criteria are not met. Hormone ablation therapy is considered an anticancer regimen. Radiation and surgery are not considered anticancer regimes.

Exclusion criteria

Exclusion Criteria:

  1. Radiation, chemotherapy, or immunotherapy or any other anticancer therapy ≤3 weeks prior to cycle 1 day 1 and mitomycin C and radioimmunotherapy 6 weeks prior to cycle 1 day 1;
  2. Except for patients with GBM/ AnaA in the Expansion Phase, patients with active CNS are excluded. Asymptomatic small lesions are not considered active. Treated lesions may be considered inactive if they are stable for at least 3 months.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
192 participants (actual)

Study arms

  • Experimental
    Arm A (Colorectal Cancer)

    Participants with colorectal cancer and liver metastasis received oral selinexor as single agent in 8 schedules, Schedule1: ≤12milligrams per meter square(mg/m\^2) 3 times weekly(TIW) during Weeks 1 and 3, twice weekly(BIW) during Weeks 2 and 4 up to 10 doses/cycle(28 days/cycle); Schedule2: \>12mg/m\^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle(28 days/cycle); Schedule3: ≥30mg/m\^2 BIW(Days 1 and 3) up to 8 doses/cycle(28 days/cycle); Schedule4: ≥20mg/m\^2 BIW(Days 1 and 2) up to 8 doses/cycle(28 days/cycle); Schedule5: ≥35mg/m\^2 BIW(Days 1 and 4) up to 8 doses(28 days/cycle); Schedule6: ≥20mg/m\^2 BIW(Days 1 and 4) after 500 mg(Week 1) to 1000 mg(Week 2 onwards) acetaminophen(given 1 hour prior to each selinexor dose) up to 8 doses/cycle (28 days/cycle); Schedule7: ≥50mg/m\^2 once weekly(QW) up to 4 doses/cycle(28 days per cycle); Schedule8: ≥45mg/m\^2 BIW(Days 1 and 3) up to 4 doses/cycle(21 days/cycle), until disease progression, death, or unacceptable toxicity.

    Drug: Selinexor · Drug: Acetaminophen

  • Experimental
    Arm B (Gynecological Cancer)

    Participants with gynecological cancer received oral selinexor as a single agent in eight schedules, Schedule 1: ≤12 mg/m\^2 TIW during Weeks 1 and 3, BIW during Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 2: \>12 mg/m\^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 3: ≥30 mg/m\^2 BIW (Days 1 and 3) up to 8 doses/cycle (28 days/cycle); Schedule 4: ≥20 mg/m\^2 BIW (Days 1 and 2) up to 8 doses/cycle (28 days/cycle); Schedule 5: ≥35 mg/m\^2 BIW (Days 1 and 4) up to 8 doses (28 days/cycle); Schedule 7: ≥50 mg/m\^2 QW up to 4 doses/cycle (28 days per cycle); Schedule 8: ≥45 mg/m\^2 BIW (Days 1 and 3) up to 4 doses/cycle (21 days/cycle), until disease progression, death, or unacceptable toxicity.

    Drug: Selinexor

  • Experimental
    Arm C (Squamous Cell Cancer)

    Participants with squamous cell cancer received oral selinexor as a single agent in eight schedules, Schedule 1: ≤12 mg/m\^2 TIW during Weeks 1 and 3, BIW during Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 2: \>12 mg/m\^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 3: ≥30 mg/m\^2 BIW (Days 1 and 3) up to 8 doses/cycle (28 days/cycle); Schedule 4: ≥20 mg/m\^2 BIW (Days 1 and 2) up to 8 doses/cycle (28 days/cycle); Schedule 5: ≥35 mg/m\^2 BIW (Days 1 and 4) up to 8 doses (28 days/cycle); Schedule 7: ≥50 mg/m\^2 QW up to 4 doses/cycle (28 days per cycle); Schedule 8: ≥45 mg/m\^2 BIW (Days 1 and 3) up to 4 doses/cycle (21 days/cycle), until disease progression, death, or unacceptable toxicity.

    Drug: Selinexor

  • Experimental
    Arm D (Castrate-resistant Prostate Cancer)

    Participants with castrate-resistant prostate cancer (CRPC) received oral selinexor as a single agent in eight schedules, Schedule 1: ≤12 mg/m\^2 TIW during Weeks 1 and 3, BIW during Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 2: \>12 mg/m\^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 3: ≥30 mg/m\^2 BIW (Days 1 and 3) up to 8 doses/cycle (28 days/cycle); Schedule 4: ≥20 mg/m\^2 BIW (Days 1 and 2) up to 8 doses/cycle (28 days/cycle); Schedule 5: ≥35 mg/m\^2 BIW (Days 1 and 4) up to 8 doses (28 days/cycle); Schedule 7: ≥50 mg/m\^2 QW up to 4 doses/cycle (28 days per cycle); Schedule 8: ≥45 mg/m\^2 BIW (Days 1 and 3) up to 4 doses/cycle (21 days/cycle), until disease progression, death, or unacceptable toxicity.

    Drug: Selinexor

  • Experimental
    Arm E (Glioblastoma Multiforme)

    Participants with glioblastoma multiforme (GBM) received oral selinexor as a single agent in eight schedules, Schedule 1: ≤12 mg/m\^2 TIW during Weeks 1 and 3, BIW during Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 2: \>12 mg/m\^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 3: ≥30 mg/m\^2 BIW (Days 1 and 3) up to 8 doses/cycle (28 days/cycle); Schedule 4: ≥20 mg/m\^2 BIW (Days 1 and 2) up to 8 doses/cycle (28 days/cycle); Schedule 5: ≥35 mg/m\^2 BIW (Days 1 and 4) up to 8 doses (28 days/cycle); Schedule 7: ≥50 mg/m\^2 QW up to 4 doses/cycle (28 days per cycle); Schedule 8: ≥45 mg/m\^2 BIW (Days 1 and 3) up to 4 doses/cycle (21 days/cycle), until disease progression, death, or unacceptable toxicity.

    Drug: Selinexor

  • Experimental
    Arm F (Melanoma)

    Participants with Melanoma received oral selinexor as a single agent in eight schedules, Schedule 1: ≤12 mg/m\^2 TIW during Weeks 1 and 3, BIW during Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 2: \>12 mg/m\^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 3: ≥30 mg/m\^2 BIW (Days 1 and 3) up to 8 doses/cycle (28 days/cycle); Schedule 4: ≥20 mg/m\^2 BIW (Days 1 and 2) up to 8 doses/cycle (28 days/cycle); Schedule 5: ≥35 mg/m\^2 BIW (Days 1 and 4) up to 8 doses (28 days/cycle); Schedule 7: ≥50 mg/m\^2 QW up to 4 doses/cycle (28 days per cycle); Schedule 8: ≥45 mg/m\^2 BIW (Days 1 and 3) up to 4 doses/cycle (21 days/cycle), until disease progression, death, or unacceptable toxicity.

    Drug: Selinexor

  • Experimental
    Arm G (Other Solid Tumors)

    Participants with other solid tumors received oral selinexor as a single agent in eight schedules, Schedule 1: ≤12 mg/m\^2 TIW during Weeks 1 and 3, BIW during Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 2: \>12 mg/m\^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 3: ≥30 mg/m\^2 BIW (Days 1 and 3) up to 8 doses/cycle (28 days/cycle); Schedule 4: ≥20 mg/m\^2 BIW (Days 1 and 2) up to 8 doses/cycle (28 days/cycle); Schedule 5: ≥35 mg/m\^2 BIW (Days 1 and 4) up to 8 doses (28 days/cycle); Schedule 7: ≥50 mg/m\^2 QW up to 4 doses/cycle (28 days per cycle); Schedule 8: ≥45 mg/m\^2 BIW (Days 1 and 3) up to 4 doses/cycle (21 days/cycle), until disease progression, death, or unacceptable toxicity.

    Drug: Selinexor

Interventions

  • Participants in this study will receive selinexor orally at dose levels specified for their respective dose cohorts. Dosing will begin at 3 mg/m\^2 twice a week and will escalate until the MTD or RP2D is determined. Cycles will be repeated in 4-week (28 days for schedule 1 to 7) and 3-week (21 days for schedule 8) intervals until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment will be permitted.

    Also known as: KPT-330, XPOVIO

  • Oral 500 mg (in Cycle 1, Week 1) to 1000 mg (in Cycle 1, Week 2 and onwards) of acetaminophen will be administered 1 hour prior to each selinexor dose up to 8 doses per cycle (28 days per cycle)

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

    An Adverse Event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAE was defined as an adverse event with an onset that occurs after receiving study drug. A serious adverse event (SAE) was defined as an AE that meets one or more of the mentioned criteria; is fatal, life threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly/birth defect, or important medical events. Number of participants with TEAEs and TESAEs were reported.

    Time frame: From start of study drug administration to 30 days after last dose of study treatment (maximum duration of 45 months)

  2. Number of Participants With Treatment-related Treatment-emergent Adverse Events

    An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAE was defined as an adverse event with an onset that occurs after receiving study drug. A treatment-related AE was any untoward medical occurrence in a clinical investigation participant administered a medicinal product; the event had a causal relationship with the treatment or usage.

    Time frame: From start of study drug administration to 30 days after last dose of study treatment (maximum duration of 45 months)

  3. Number of Participants With Treatment-emergent Adverse Events (TEAEs) Greater Than or Equal to Grade 3, Based on National Cancer Institute Common Terminology Criteria (NCI-CTCAE), Version 4.03

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. As per NCI-CTCAE version 4.03, Grade 1: asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily life (ADL); Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of existing hospitalization indicated, disabling, limiting self-care ADL; Grade 4: life-threatening consequence, urgent intervention indicated; Grade 5: death related to AE. A treatment related AE was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event had a causal relationship with the treatment or usage.

    Time frame: From start of study drug administration to 30 days after last dose of study treatment (maximum duration of 45 months)

  4. Number of Participants Who Experienced Dose Limiting Toxicity (DLT)

    Evaluation of DLTs was only conducted in participants who participated in the Dose-escalation Phase. A DLT was defined as any of the following, considered possibly related to drug administration, occurring in the first 28 days (or 21 days for participants on Schedule 8) at the target dose (ie, for Schedule 2 this meant the first 4 weeks after the 12 mg/m2 run-in week): Missed selinexor doses due to drug-related toxicities, discontinuation of a participant due to a toxicity that was at least possibly related to study drug before completing Cycle 1.

    Time frame: Cycle 1 only (28-day cycle)

  5. Recommended Phase 2 Dose (RP2D)

    The RP2D was the maximum tolerated dose (MTD) or less. MTD was defined as the next lower dose level below the one in which \>1 of 3 participants or ≥2 of 6 participants experienced DLT, provided that dose level was ≤25 percent (%) lower than the highest (intolerable) dose tested. If the projected MTD was \>25% lower than the highest dose tested, then an additional cohort of ≥3 participants was added at a dose that was intermediate between the intolerable dose and the next lower dose.

    Time frame: From start of study drug administration to 30 days after last dose of study treatment (maximum duration of 45 months)

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of Selinexor

    Cmax was defined as maximum observed concentration, taken directly from the plasma concentration data.

    Time frame: Cycle1, Day1: Pre-dose, 30, 60, 120, 240, 480 minutes

  2. Time of Maximum Observed Concentration in Plasma (Tmax) of Selinexor

    Tmax was defined as time of first observation of Cmax, taken directly from the plasma concentration data.

    Time frame: Cycle1, Day1: Pre-dose, 30, 60, 120, 240, 480 minutes

  3. Area Under the Concentration Time Curve From the Time of Dosing to Time in Plasma (AUC0-t) of Selinexor

    AUC0-t was defined as area under the concentration-time curve from time zero to the last non-zero concentration.

    Time frame: Cycle1, Day1: Pre-dose, 30, 60, 120, 240, 480 minutes

  4. Area Under the Concentration Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of Selinexor

    AUC0-inf was defined as area under the concentration-time curve from time zero to infinity (extrapolated). It was calculated as AUC0-t + Ct/kel, where: Ct = the last observed non-zero concentration and Kel = elimination rate constant.

    Time frame: Cycle1, Day1: Pre-dose, 30, 60, 120, 240, 480 minutes

  5. Elimination Half-Life (t1/2) of Selinexor

    t1/2 was defined as elimination half-life, it was calculated as ln(2)/kel, where In = natural logarithm and kel = elimination rate constant.

    Time frame: Cycle1, Day1: Pre-dose, 30, 60, 120, 240, 480 minutes

  6. Apparent Total Body Clearance (CL/F) of Selinexor

    CL/F was calculated as Dose/AUC0-inf, uncorrected for fraction absorbed; reported normalized by participant body weight (kilogram).

    Time frame: Cycle1, Day1: Pre-dose, 30, 60, 120, 240, 480 minutes

  7. Apparent Volume of Distribution of Selinexor (Vd/F)

    Vd/F was calculated as Dose/(kel \* AUC0-inf), uncorrected for fraction absorbed; reported normalized by participant body weight (kilogram).

    Time frame: Cycle1, Day1: Pre-dose, 30, 60, 120, 240, 480 minutes

  8. Number of Participants With Best Overall Response (BOR)

    BOR is response recorded from start of treatment until disease progression/recurrence. Best lesion response was defined by Recist Criteria V1 (for target and non-target lesions) and RANO criteria (for glioblastoma multiforme): complete response (CR)- disappearance of all target lesions. Any pathological lymph nodes (target/non target) must have reduction in short axis to less than (\<) 10 mm; partial response (PR)- at least 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum longest diameter; stable disease (SD)- steady state of disease. Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD; progressive disease (PD): at least 20% increase in sum of diameters of measured lesions taking as references smallest sum of diameters recorded since treatment started. In addition to relative increase of 20%, sum must also demonstrate an absolute increase of at least 5 mm, or appearance of one or more new lesions.

    Time frame: Up to maximum duration of 45 months

  9. Percentage of Participants With Objective Response

    Objective response rate (ORR) was determined as percentage of participants who had either CR or PR, as defined by RECIST v1.1 (for solid tumors). CR was defined as disappearance of all target lesions. Any pathological lymph nodes (target/non target) must have reduction in short axis to \<10 mm and PR was defined as at least 30% decrease in sum of diameters of target lesions. ORR was calculated as a proportion and included a 2 sided 95% CI using the exact (Clopper-Pearson) method.

    Time frame: Up to maximum duration of 45 months

  10. Duration of Stable Disease (SD)

    Duration of stable disease was defined as the time from the date of first dose to first documented radiologic evidence of disease recurrence or progression, as defined by RECIST v1.1 (for solid tumors) or RANO criteria (for GBM and AnaA).

    Time frame: From first dose of study drug administration to first documented evidence of disease recurrence or progression (maximum duration of 45 months)

  11. Progression-free Survival (PFS)

    Progression-free survival was calculated from the date of first dose of study treatment to first documented evidence of disease recurrence or progression or death due to any cause. Patients who are last known to be alive and without evidence of progression will be censored at time of last evaluable disease assessment. If date of progression or death occurred after more than 1 missed disease assessment interval, patients are censored at the time of last evaluable disease assessment prior to the missed assessment. Progressive disease was defined as at least a 20% increase in the sum of diameters of measured lesions taking as references the smallest sum of diameters recorded since the treatment started. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Appearance of one or more new lesions also constituted progressive disease.

    Time frame: From start of study drug administration until PD or discontinuation from the study or death (maximum duration of 45 months)

  12. Overall Survival (OS)

    OS was calculated from the date of first dose to date of death. Participants who were still alive prior to the data cutoff for final efficacy analysis, or who dropout prior to study end, were censored at the day they were last known to be alive. The OS was calculated using the Kaplan-Meier method.

    Time frame: From first dose of study drug administration to date of death (maximum duration of 45 months)

07

Results

Posted Apr 30, 2021

Participant flow

The study was conducted at six centers in United States, Canada, and Denmark from 18 June 2012 and 15 March 2016.

Participant flow — Overall Study
MilestoneArm A (Colorectal Cancer)Arm B (Gynecological Cancer)Arm C (Squamous Cell Cancer)Arm D (Castrate-resistant Prostate Cancer)Arm E (Glioblastoma Multiforme)Arm F (Melanoma)Arm G (Other Solid Tumors)
Started6020212171547
Received study drug5920212161547
Low dose (<30 mg/m^2)16530028
Medium dose (>=30 mg/m^2 and <55 mg/m^2)27111586321
High dose (>= 55 mg/m^2)16431301018
Completed0000000
Not completed6020212171547
Withdrew: Withdrawal by participant72460412
Withdrew: Incidence or severity of aes5113028
Withdrew: Disease progression441615116721
Withdrew: Non-compliance with study procedures0000001
Withdrew: Death1111003
Withdrew: Other treatments become available1000001
Withdrew: Investigator discretion0000010
Withdrew: Other1000001
Withdrew: Randomized but not treated1000110

Outcome measures

PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

An Adverse Event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAE was defined as an adverse event with an onset that occurs after receiving study drug. A serious adverse event (SAE) was defined as an AE that meets one or more of the mentioned criteria; is fatal, life threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly/birth defect, or important medical events. Number of participants with TEAEs and TESAEs were reported.

Time frame:
From start of study drug administration to 30 days after last dose of study treatment (maximum duration of 45 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
ParticipantsArm A (Colorectal Cancer)Arm B (Gynecological Cancer)Arm C (Squamous Cell Cancer)Arm D (Castrate-resistant Prostate Cancer)Arm E (Glioblastoma Multiforme)Arm F (Melanoma)Arm G (Other Solid Tumors)
Participants with TEAEs5920212161546
Participants with TESAEs3013982524
PrimaryNumber of Participants With Treatment-related Treatment-emergent Adverse Events

An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAE was defined as an adverse event with an onset that occurs after receiving study drug. A treatment-related AE was any untoward medical occurrence in a clinical investigation participant administered a medicinal product; the event had a causal relationship with the treatment or usage.

Time frame:
From start of study drug administration to 30 days after last dose of study treatment (maximum duration of 45 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-related Treatment-emergent Adverse Events
ParticipantsArm A (Colorectal Cancer)Arm B (Gynecological Cancer)Arm C (Squamous Cell Cancer)Arm D (Castrate-resistant Prostate Cancer)Arm E (Glioblastoma Multiforme)Arm F (Melanoma)Arm G (Other Solid Tumors)
Participants with Treatment-related TEAEs5919202161445
Participants with Treatment-related TESAEs6214119
PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) Greater Than or Equal to Grade 3, Based on National Cancer Institute Common Terminology Criteria (NCI-CTCAE), Version 4.03

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. As per NCI-CTCAE version 4.03, Grade 1: asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily life (ADL); Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of existing hospitalization indicated, disabling, limiting self-care ADL; Grade 4: life-threatening consequence, urgent intervention indicated; Grade 5: death related to AE. A treatment related AE was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event had a causal relationship with the treatment or usage.

Time frame:
From start of study drug administration to 30 days after last dose of study treatment (maximum duration of 45 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) Greater Than or Equal to Grade 3, Based on National Cancer Institute Common Terminology Criteria (NCI-CTCAE), Version 4.03
ParticipantsArm A (Colorectal Cancer)Arm B (Gynecological Cancer)Arm C (Squamous Cell Cancer)Arm D (Castrate-resistant Prostate Cancer)Arm E (Glioblastoma Multiforme)Arm F (Melanoma)Arm G (Other Solid Tumors)
Number of Participants With Treatment-emergent Adverse Events (TEAEs) Greater Than or Equal to Grade 3, Based on National Cancer Institute Common Terminology Criteria (NCI-CTCAE), Version 4.035017161741135
PrimaryNumber of Participants Who Experienced Dose Limiting Toxicity (DLT)

Evaluation of DLTs was only conducted in participants who participated in the Dose-escalation Phase. A DLT was defined as any of the following, considered possibly related to drug administration, occurring in the first 28 days (or 21 days for participants on Schedule 8) at the target dose (ie, for Schedule 2 this meant the first 4 weeks after the 12 mg/m2 run-in week): Missed selinexor doses due to drug-related toxicities, discontinuation of a participant due to a toxicity that was at least possibly related to study drug before completing Cycle 1.

Time frame:
Cycle 1 only (28-day cycle)
Reported as:
Count of participants · Participants
Number of Participants Who Experienced Dose Limiting Toxicity (DLT)
ParticipantsArm A (Colorectal Cancer)Arm B (Gynecological Cancer)Arm C (Squamous Cell Cancer)Arm D (Castrate-resistant Prostate Cancer)Arm E (Glioblastoma Multiforme)Arm F (Melanoma)Arm G (Other Solid Tumors)
Number of Participants Who Experienced Dose Limiting Toxicity (DLT)1000012
PrimaryRecommended Phase 2 Dose (RP2D)

The RP2D was the maximum tolerated dose (MTD) or less. MTD was defined as the next lower dose level below the one in which \>1 of 3 participants or ≥2 of 6 participants experienced DLT, provided that dose level was ≤25 percent (%) lower than the highest (intolerable) dose tested. If the projected MTD was \>25% lower than the highest dose tested, then an additional cohort of ≥3 participants was added at a dose that was intermediate between the intolerable dose and the next lower dose.

Time frame:
From start of study drug administration to 30 days after last dose of study treatment (maximum duration of 45 months)
Reported as:
Number · mg/m^2
Recommended Phase 2 Dose (RP2D)
mg/m^2Arms A to G: Overall Solid Tumor Malignancies
Recommended Phase 2 Dose (RP2D)35
SecondaryMaximum Observed Plasma Concentration (Cmax) of Selinexor

Cmax was defined as maximum observed concentration, taken directly from the plasma concentration data.

Time frame:
Cycle1, Day1: Pre-dose, 30, 60, 120, 240, 480 minutes
Reported as:
Geometric mean · nanogram per milliliter
Maximum Observed Plasma Concentration (Cmax) of Selinexor
nanogram per milliliterSelinexor Dose: 3 mg/m^2Selinexor Dose: 6 mg/m^2Selinexor Dose: 12 mg/m^2Selinexor Dose: 16.8 mg/m^2Selinexor Dose: 20 mg/m^2Selinexor Dose: 23 mg/m^2Selinexor Dose: 28 mg/m^2Selinexor Dose: 30 mg/m^2Selinexor Dose: 35 mg/m^2Selinexor Dose: 39 mg/m^2Selinexor Dose: 40 mg/m^2Selinexor Dose: 45 mg/m^2Selinexor Dose: 50 mg/m^2Selinexor Dose: 55 mg/m^2Selinexor Dose: 58 mg/m^2Selinexor Dose: 65 mg/m^2Selinexor Dose: 70 mg/m^2Selinexor Dose: 80 mg/m^2Selinexor Dose: 85 mg/m^2
Maximum Observed Plasma Concentration (Cmax) of Selinexor3075 ± 38.2149 ± 32168220 ± 44.5308 ± 12.1293 ± 58.3413 ± 46.7349 ± 25.4528 ± 12.5442 ± 63.6390 ± 25.3507 ± 57.8505 ± 18.2561 ± 45.4896 ± 71.7521765 ± 6.61371 ± 31.1
SecondaryTime of Maximum Observed Concentration in Plasma (Tmax) of Selinexor

Tmax was defined as time of first observation of Cmax, taken directly from the plasma concentration data.

Time frame:
Cycle1, Day1: Pre-dose, 30, 60, 120, 240, 480 minutes
Reported as:
Median · hours
Time of Maximum Observed Concentration in Plasma (Tmax) of Selinexor
hoursSelinexor Dose: 3 mg/m^2Selinexor Dose: 6 mg/m^2Selinexor Dose: 12 mg/m^2Selinexor Dose: 16.8 mg/m^2Selinexor Dose: 20 mg/m^2Selinexor Dose: 23 mg/m^2Selinexor Dose: 28 mg/m^2Selinexor Dose: 30 mg/m^2Selinexor Dose: 35 mg/m^2Selinexor Dose: 39 mg/m^2Selinexor Dose: 40 mg/m^2Selinexor Dose: 45 mg/m^2Selinexor Dose: 50 mg/m^2Selinexor Dose: 55 mg/m^2Selinexor Dose: 58 mg/m^2Selinexor Dose: 65 mg/m^2Selinexor Dose: 70 mg/m^2Selinexor Dose: 80 mg/m^2Selinexor Dose: 85 mg/m^2
Time of Maximum Observed Concentration in Plasma (Tmax) of Selinexor12.1 (0.9 to 7.5)2.0 (1.0 to 7.7)2.12.3 (2.0 to 7.5)2.1 (1.1 to 8.0)3.1 (0.5 to 7.6)2.9 (0.5 to 7.7)3.8 (2.0 to 7.8)3.1 (1.0 to 4.3)3.9 (2.1 to 4.2)4.2 (2.1 to 8.0)3.0 (1.0 to 4.1)3.8 (1.1 to 4.0)3.1 (2.2 to 4.2)2.0 (0.6 to 7.5)8.03.9 (3.8 to 4.0)3.9 (3.8 to 3.9)
SecondaryArea Under the Concentration Time Curve From the Time of Dosing to Time in Plasma (AUC0-t) of Selinexor

AUC0-t was defined as area under the concentration-time curve from time zero to the last non-zero concentration.

Time frame:
Cycle1, Day1: Pre-dose, 30, 60, 120, 240, 480 minutes
Reported as:
Geometric mean · nanogram hour per milliliter
Area Under the Concentration Time Curve From the Time of Dosing to Time in Plasma (AUC0-t) of Selinexor
nanogram hour per milliliterSelinexor Dose: 3 mg/m^2Selinexor Dose: 6 mg/m^2Selinexor Dose: 12 mg/m^2Selinexor Dose: 16.8 mg/m^2Selinexor Dose: 20 mg/m^2Selinexor Dose: 23 mg/m^2Selinexor Dose: 28 mg/m^2Selinexor Dose: 30 mg/m^2Selinexor Dose: 35 mg/m^2Selinexor Dose: 39 mg/m^2Selinexor Dose: 40 mg/m^2Selinexor Dose: 45 mg/m^2Selinexor Dose: 50 mg/m^2Selinexor Dose: 55 mg/m^2Selinexor Dose: 58 mg/m^2Selinexor Dose: 65 mg/m^2Selinexor Dose: 70 mg/m^2Selinexor Dose: 80 mg/m^2Selinexor Dose: 85 mg/m^2
Area Under the Concentration Time Curve From the Time of Dosing to Time in Plasma (AUC0-t) of Selinexor333707 ± 13.61578 ± 21.013692446 ± 23.33387 ± 17.73106 ± 313861 ± 16.63691 ± 25.04885 ± 15.35255 ± 24.44390 ± 24.95490 ± 3.15803 ± 23.55888 ± 18.98482 ± 44.872109838 ± 12.711485 ± 20.1
SecondaryArea Under the Concentration Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of Selinexor

AUC0-inf was defined as area under the concentration-time curve from time zero to infinity (extrapolated). It was calculated as AUC0-t + Ct/kel, where: Ct = the last observed non-zero concentration and Kel = elimination rate constant.

Time frame:
Cycle1, Day1: Pre-dose, 30, 60, 120, 240, 480 minutes
Reported as:
Geometric mean · nanogram hour per milliliter
Area Under the Concentration Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of Selinexor
nanogram hour per milliliterSelinexor Dose: 3 mg/m^2Selinexor Dose: 6 mg/m^2Selinexor Dose: 12 mg/m^2Selinexor Dose: 16.8 mg/m^2Selinexor Dose: 20 mg/m^2Selinexor Dose: 23 mg/m^2Selinexor Dose: 28 mg/m^2Selinexor Dose: 30 mg/m^2Selinexor Dose: 35 mg/m^2Selinexor Dose: 39 mg/m^2Selinexor Dose: 40 mg/m^2Selinexor Dose: 45 mg/m^2Selinexor Dose: 50 mg/m^2Selinexor Dose: 55 mg/m^2Selinexor Dose: 58 mg/m^2Selinexor Dose: 65 mg/m^2Selinexor Dose: 70 mg/m^2Selinexor Dose: 80 mg/m^2Selinexor Dose: 85 mg/m^2
Area Under the Concentration Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of Selinexor355808 ± 5.21613 ± 21.414552269 ± 27.23332 ± 17.339363961 ± 12.14585 ± 18.25014 ± 18.05294 ± 24.033955688 ± 0.65894 ± 24.86567 ± 12.810265 ± 31.4—902511830 ± 20.1
SecondaryElimination Half-Life (t1/2) of Selinexor

t1/2 was defined as elimination half-life, it was calculated as ln(2)/kel, where In = natural logarithm and kel = elimination rate constant.

Time frame:
Cycle1, Day1: Pre-dose, 30, 60, 120, 240, 480 minutes
Reported as:
Median · hours
Elimination Half-Life (t1/2) of Selinexor
hoursSelinexor Dose: 3 mg/m^2Selinexor Dose: 6 mg/m^2Selinexor Dose: 12 mg/m^2Selinexor Dose: 16.8 mg/m^2Selinexor Dose: 20 mg/m^2Selinexor Dose: 23 mg/m^2Selinexor Dose: 28 mg/m^2Selinexor Dose: 30 mg/m^2Selinexor Dose: 35 mg/m^2Selinexor Dose: 39 mg/m^2Selinexor Dose: 40 mg/m^2Selinexor Dose: 45 mg/m^2Selinexor Dose: 50 mg/m^2Selinexor Dose: 55 mg/m^2Selinexor Dose: 58 mg/m^2Selinexor Dose: 65 mg/m^2Selinexor Dose: 70 mg/m^2Selinexor Dose: 80 mg/m^2Selinexor Dose: 85 mg/m^2
Elimination Half-Life (t1/2) of Selinexor6.25.6 (4.8 to 6.4)5.0 (4.1 to 7.8)5.75.6 (4.2 to 7.5)5.8 (5.7 to 6.4)5.76.5 (4.1 to 7.9)6.0 (4.0 to 7.0)5.9 (3.5 to 6.2)6.9 (5.4 to 7.2)7.37.3 (7.1 to 7.5)6.2 (5.0 to 10.1)6.5 (5.6 to 7.1)6.9 (5.5 to 9.3)—5.75.3 (4.6 to 6.0)
SecondaryApparent Total Body Clearance (CL/F) of Selinexor

CL/F was calculated as Dose/AUC0-inf, uncorrected for fraction absorbed; reported normalized by participant body weight (kilogram).

Time frame:
Cycle1, Day1: Pre-dose, 30, 60, 120, 240, 480 minutes
Reported as:
Geometric mean · liter per hour per kilogram
Apparent Total Body Clearance (CL/F) of Selinexor
liter per hour per kilogramSelinexor Dose: 3 mg/m^2Selinexor Dose: 6 mg/m^2Selinexor Dose: 12 mg/m^2Selinexor Dose: 16.8 mg/m^2Selinexor Dose: 20 mg/m^2Selinexor Dose: 23 mg/m^2Selinexor Dose: 28 mg/m^2Selinexor Dose: 30 mg/m^2Selinexor Dose: 35 mg/m^2Selinexor Dose: 39 mg/m^2Selinexor Dose: 40 mg/m^2Selinexor Dose: 45 mg/m^2Selinexor Dose: 50 mg/m^2Selinexor Dose: 55 mg/m^2Selinexor Dose: 58 mg/m^2Selinexor Dose: 65 mg/m^2Selinexor Dose: 70 mg/m^2Selinexor Dose: 80 mg/m^2Selinexor Dose: 85 mg/m^2
Apparent Total Body Clearance (CL/F) of Selinexor0.200.18 ± 7.90.19 ± 160.200.19 ± 270.19 ± 26.10.180.17 ± 16.80.20 ± 26.70.20 ± 12.50.19 ± 24.40.270.18 ± 10.60.20 ± 17.10.20 ± 17.00.15 ± 32.7—0.220.18 ± 4.1
SecondaryApparent Volume of Distribution of Selinexor (Vd/F)

Vd/F was calculated as Dose/(kel \* AUC0-inf), uncorrected for fraction absorbed; reported normalized by participant body weight (kilogram).

Time frame:
Cycle1, Day1: Pre-dose, 30, 60, 120, 240, 480 minutes
Reported as:
Geometric mean · liter per kilogram
Apparent Volume of Distribution of Selinexor (Vd/F)
liter per kilogramSelinexor Dose: 3 Milligram Per Square Meter (mg/m2)Selinexor Dose: 6 mg/m2Selinexor Dose: 12 mg/m2Selinexor Dose: 16.8 mg/m2Selinexor Dose: 20 mg/m2Selinexor Dose: 23 mg/m2Selinexor Dose: 28 mg/m2Selinexor Dose: 30 mg/m2Selinexor Dose: 35 mg/m2Selinexor Dose: 39 mg/m2Selinexor Dose: 40 mg/m2Selinexor Dose: 45 mg/m2Selinexor Dose: 50 mg/m2Selinexor Dose: 55 mg/m2Selinexor Dose: 58 mg/m2Selinexor Dose: 65 mg/m2Selinexor Dose: 70 mg/m2Selinexor Dose: 80 mg/m2Selinexor Dose: 85 mg/m2
Apparent Volume of Distribution of Selinexor (Vd/F)1.81.4 ± 12.51.4 ± 22.51.61.6 ± 20.91.6 ± 21.21.51.6 ± 6.61.6 ± 26.61.5 ± 26.11.9 ± 31.12.81.9 ± 14.31.9 ± 24.71.8 ± 15.41.5 ± 31.8—1.81.4 ± 22.7
SecondaryNumber of Participants With Best Overall Response (BOR)

BOR is response recorded from start of treatment until disease progression/recurrence. Best lesion response was defined by Recist Criteria V1 (for target and non-target lesions) and RANO criteria (for glioblastoma multiforme): complete response (CR)- disappearance of all target lesions. Any pathological lymph nodes (target/non target) must have reduction in short axis to less than (\<) 10 mm; partial response (PR)- at least 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum longest diameter; stable disease (SD)- steady state of disease. Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD; progressive disease (PD): at least 20% increase in sum of diameters of measured lesions taking as references smallest sum of diameters recorded since treatment started. In addition to relative increase of 20%, sum must also demonstrate an absolute increase of at least 5 mm, or appearance of one or more new lesions.

Time frame:
Up to maximum duration of 45 months
Reported as:
Count of participants · Participants
Number of Participants With Best Overall Response (BOR)
ParticipantsArm A (Colorectal Cancer)Arm B (Gynecological Cancer)Arm C (Squamous Cell Cancer)Arm D (Castrate-resistant Prostate Cancer)Arm E (Glioblastoma Multiforme)Arm F (Melanoma)Arm G (Other Solid Tumors)
Complete Response0000010
Partial Response1300011
Stable Disease1595110320
Progression (Objective)286855410
Progressive Disease due to symptomatic deterioration4030011
Not Evaluable92531414
SecondaryPercentage of Participants With Objective Response

Objective response rate (ORR) was determined as percentage of participants who had either CR or PR, as defined by RECIST v1.1 (for solid tumors). CR was defined as disappearance of all target lesions. Any pathological lymph nodes (target/non target) must have reduction in short axis to \<10 mm and PR was defined as at least 30% decrease in sum of diameters of target lesions. ORR was calculated as a proportion and included a 2 sided 95% CI using the exact (Clopper-Pearson) method.

Time frame:
Up to maximum duration of 45 months
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Response
percentage of participantsArm A (Colorectal Cancer)Arm B (Gynecological Cancer)Arm C (Squamous Cell Cancer)Arm D (Castrate-resistant Prostate Cancer)Arm E (Glioblastoma Multiforme)Arm F (Melanoma)Arm G (Other Solid Tumors)
Percentage of Participants With Objective Response1.815.000014.32.2
SecondaryDuration of Stable Disease (SD)

Duration of stable disease was defined as the time from the date of first dose to first documented radiologic evidence of disease recurrence or progression, as defined by RECIST v1.1 (for solid tumors) or RANO criteria (for GBM and AnaA).

Time frame:
From first dose of study drug administration to first documented evidence of disease recurrence or progression (maximum duration of 45 months)
Reported as:
Median · Days
Duration of Stable Disease (SD)
DaysArm A (Colorectal Cancer)Arm B (Gynecological Cancer)Arm C (Squamous Cell Cancer)Arm D (Castrate-resistant Prostate Cancer)Arm E (Glioblastoma Multiforme)Arm F (Melanoma)Arm G (Other Solid Tumors)
Duration of Stable Disease (SD)53 (52 to 59)119 (42 to 310)52 (46 to 79)133 (53 to 484)43 (38 to 55)52 (22 to 539)134 (53 to 267)
SecondaryProgression-free Survival (PFS)

Progression-free survival was calculated from the date of first dose of study treatment to first documented evidence of disease recurrence or progression or death due to any cause. Patients who are last known to be alive and without evidence of progression will be censored at time of last evaluable disease assessment. If date of progression or death occurred after more than 1 missed disease assessment interval, patients are censored at the time of last evaluable disease assessment prior to the missed assessment. Progressive disease was defined as at least a 20% increase in the sum of diameters of measured lesions taking as references the smallest sum of diameters recorded since the treatment started. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Appearance of one or more new lesions also constituted progressive disease.

Time frame:
From start of study drug administration until PD or discontinuation from the study or death (maximum duration of 45 months)
Reported as:
Median · Days
Progression-free Survival (PFS)
DaysArm A (Colorectal Cancer)Arm B (Gynecological Cancer)Arm C (Squamous Cell Cancer)Arm D (Castrate-resistant Prostate Cancer)Arm E (Glioblastoma Multiforme)Arm F (Melanoma)Arm G (Other Solid Tumors)
Progression-free Survival (PFS)53 (52 to 59)119 (42 to 310)52 (44 to 79)127 (53 to 322)41 (38 to 55)52 (22 to 539)88 (53 to 234)
SecondaryOverall Survival (OS)

OS was calculated from the date of first dose to date of death. Participants who were still alive prior to the data cutoff for final efficacy analysis, or who dropout prior to study end, were censored at the day they were last known to be alive. The OS was calculated using the Kaplan-Meier method.

Time frame:
From first dose of study drug administration to date of death (maximum duration of 45 months)
Reported as:
Median · Days
Overall Survival (OS)
DaysArm A (Colorectal Cancer)Arm B (Gynecological Cancer)Arm C (Squamous Cell Cancer)Arm D (Castrate-resistant Prostate Cancer)Arm E (Glioblastoma Multiforme)Arm F (Melanoma)Arm G (Other Solid Tumors)
Overall Survival (OS)136 (102 to 532)491 (167 to NA)161 (62 to 460)354 (322 to NA)103 (38 to 152)NA (125 to NA)290 (263 to NA)

Adverse events

Collected over From start of study drug administration to 30 days after last dose of study treatment (maximum duration of 45 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A (Colorectal Cancer)—30/59 (50.8%)59/59 (100%)
Arm B (Gynecological Cancer)—13/20 (65%)20/20 (100%)
Arm C (Squamous Cell Cancer)—9/21 (42.9%)21/21 (100%)
Arm D (Castrate-resistant Prostate Cancer)—8/21 (38.1%)21/21 (100%)
Arm E (Glioblastoma Multiforme)—2/6 (33.3%)6/6 (100%)
Arm F (Melanoma)—5/15 (33.3%)15/15 (100%)
Arm G (Other Solid Tumors)—24/47 (51.1%)46/47 (97.9%)
Most frequent serious events
Showing 10 of 78
Most frequent serious events
EventArm A (Colorectal Cancer)Arm B (Gynecological Cancer)Arm C (Squamous Cell Cancer)Arm D (Castrate-resistant Prostate Cancer)Arm E (Glioblastoma Multiforme)Arm F (Melanoma)Arm G (Other Solid Tumors)
ThrombocytopeniaBlood and lymphatic system disorders0/590/200/210/211/60/152/47
AnaemiaBlood and lymphatic system disorders0/590/200/211/211/60/150/47
Lung infectionInfections and infestations2/592/201/210/211/60/152/47
HyperglycaemiaMetabolism and nutrition disorders1/590/200/210/211/60/150/47
LethargyNervous system disorders0/590/200/210/211/60/150/47
EmbolismVascular disorders0/591/200/211/211/60/150/47
Small intestinal obstructionGastrointestinal disorders1/593/200/210/210/60/150/47
DyspnoeaRespiratory, thoracic and mediastinal disorders2/590/200/210/210/62/152/47
Large intestinal obstructionGastrointestinal disorders1/592/201/210/210/60/150/47
FatigueGeneral disorders2/592/200/210/210/60/151/47
Most frequent other events
Showing 10 of 198
Most frequent other events
EventArm A (Colorectal Cancer)Arm B (Gynecological Cancer)Arm C (Squamous Cell Cancer)Arm D (Castrate-resistant Prostate Cancer)Arm E (Glioblastoma Multiforme)Arm F (Melanoma)Arm G (Other Solid Tumors)
NauseaGastrointestinal disorders46/5919/2012/219/213/611/1538/47
VomitingGastrointestinal disorders35/5917/2011/217/212/65/1527/47
FatigueGeneral disorders46/5916/2014/2117/215/610/1536/47
Decreased appetiteMetabolism and nutrition disorders42/5913/2011/2114/215/69/1533/47
Weight decreasedInvestigations32/598/2011/2110/214/67/1519/47
AnaemiaBlood and lymphatic system disorders23/5913/2013/2110/213/64/1521/47
HyponatraemiaMetabolism and nutrition disorders36/598/207/216/211/69/1517/47
ThrombocytopeniaBlood and lymphatic system disorders26/596/209/2112/213/68/1523/47
DiarrhoeaGastrointestinal disorders24/5911/208/217/211/67/1516/47
ConstipationGastrointestinal disorders21/599/206/2111/211/65/1522/47

Baseline characteristics

Safety Population included all participants who received at least one dose of selinexor. As pre-specified in the study Protocol data were not collected per dose level. The limited data available based on cancer stratification as pre-specified in the protocol is presented.

Age, Continuous
Age, Continuous(years)Arm A (Colorectal Cancer)Arm B (Gynecological Cancer)Arm C (Squamous Cell Cancer)Arm D (Castrate-resistant Prostate Cancer)Arm E (Glioblastoma Multiforme)Arm F (Melanoma)Arm G (Other Solid Tumors)Total
Mean59.8 ± 11.3555.0 ± 12.5459.2 ± 7.3968.7 ± 7.6956.0 ± 14.9467.7 ± 11.0457.7 ± 12.6760.2 ± 11.82
Sex: Female, Male
Sex: Female, Male(Participants)Arm A (Colorectal Cancer)Arm B (Gynecological Cancer)Arm C (Squamous Cell Cancer)Arm D (Castrate-resistant Prostate Cancer)Arm E (Glioblastoma Multiforme)Arm F (Melanoma)Arm G (Other Solid Tumors)Total
Female252090341475
Male340122131133114
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A (Colorectal Cancer)Arm B (Gynecological Cancer)Arm C (Squamous Cell Cancer)Arm D (Castrate-resistant Prostate Cancer)Arm E (Glioblastoma Multiforme)Arm F (Melanoma)Arm G (Other Solid Tumors)Total
American Indian or Alaska Native00010001
Asian32000016
Native Hawaiian or Other Pacific Islander00000000
Black or African American1004201522
White4518171661441157
More than one race00000000
Unknown or Not Reported10020003
08

Study locations

6 sites
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10065, United States
  • Gabrail Cancer Center
    Canton, Ohio 44718, United States
  • Princess Margaret Hospital
    Toronto, Ontario M5T 2M9, Canada
  • Rigshospitalet
    Copenhagen, 2100, Denmark
09

References and documents

Publications

  • Machlus KR, Wu SK, Vijey P, Soussou TS, Liu ZJ, Shacham E, Unger TJ, Kashyap T, Klebanov B, Sola-Visner M, Crochiere M, Italiano JE Jr, Landesman Y. Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis. Blood. 2017 Aug 31;130(9):1132-1143. doi: 10.1182/blood-2016-11-752840. Epub 2017 Jun 19. PubMed 28630120 ↗

Individual participant data

Plan to share: Yes

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2012 to primary completion in Mar 2016, 44 months.

Results were first posted in Apr 2021, 5 years 1 month after primary completion.

Of 45 phase 1 interventional studies under Carcinoma, Squamous Cell, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 62. This study's 44 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2012
First posted
May 30, 2012
StartActual
Jun 18, 2012
Primary completionActual
Mar 15, 2016
CompletionActual
Mar 15, 2016
Results first posted
Apr 30, 2021
Last update
Jan 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01607905
Responsible party
Sponsor
First posted
May 30, 2012
Start date
Jun 18, 2012
Primary completion
Mar 15, 2016
Completion
Mar 15, 2016
Results posted
Apr 30, 2021
Last update
Jan 26, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selinexor

Start the discussion